small molecule

INDOMETHACIN

INDOMETHACIN

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameINDOMETHACIN
Active ingredientINDOMETHACIN
Strength50MG
Dosage formSUPPOSITORY
RouteRECTAL
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.